Sotera Health Company $SHC Shares Bought by TD Asset Management Inc

Key Points

• TD Asset Management Inc increased its stake in Sotera Health Company (NASDAQ:SHC) by 10.9%, now holding 200,922 shares valued at approximately $2.23 million.
• Institutional investors collectively own 91.03% of Sotera Health's shares, indicating strong institutional confidence in the company.
• Sotera Health's recent quarterly earnings surpassed expectations, reporting $0.20 EPS against a consensus estimate of $0.17 EPS, with revenue of $294.34 million.

TD Asset Management Inc boosted its stake in shares of Sotera Health Company (NASDAQ:SHC - Free Report) by 10.9% during the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 200,922 shares of the company's stock after buying an additional 19,698 shares during the period. TD Asset Management Inc owned 0.07% of Sotera Health worth $2,234,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in SHC. TPG GP A LLC acquired a new position in shares of Sotera Health in the 1st quarter valued at $79,126,000. Sculptor Capital LP lifted its stake in shares of Sotera Health by 80.8% in the 1st quarter. Sculptor Capital LP now owns 9,037,511 shares of the company's stock valued at $105,377,000 after purchasing an additional 4,037,511 shares during the last quarter. T. Rowe Price Investment Management Inc. lifted its stake in shares of Sotera Health by 5.9% in the 1st quarter. T. Rowe Price Investment Management Inc. now owns 8,045,502 shares of the company's stock valued at $93,811,000 after purchasing an additional 450,761 shares during the last quarter. Two Seas Capital LP lifted its stake in shares of Sotera Health by 14.7% in the 1st quarter. Two Seas Capital LP now owns 3,321,136 shares of the company's stock valued at $38,724,000 after purchasing an additional 425,000 shares during the last quarter. Finally, Nuveen LLC acquired a new position in shares of Sotera Health in the 1st quarter valued at $4,433,000. Institutional investors and hedge funds own 91.03% of the company's stock.

Sotera Health Price Performance

SHC stock opened at $16.62 on Wednesday. The company has a current ratio of 2.47, a quick ratio of 2.23 and a debt-to-equity ratio of 4.49. The company has a market capitalization of $4.72 billion, a PE ratio of 207.78 and a beta of 1.82. Sotera Health Company has a 12-month low of $9.53 and a 12-month high of $17.04. The business's fifty day moving average price is $16.02 and its 200 day moving average price is $13.23.

Sotera Health (NASDAQ:SHC - Get Free Report) last posted its quarterly earnings data on Friday, August 8th. The company reported $0.20 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.17 by $0.03. The firm had revenue of $294.34 million for the quarter, compared to the consensus estimate of $275.81 million. Sotera Health had a return on equity of 39.42% and a net margin of 2.14%.The company's quarterly revenue was up 6.4% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.19 EPS. Sotera Health has set its FY 2025 guidance at 0.750-0.820 EPS. On average, sell-side analysts anticipate that Sotera Health Company will post 0.61 EPS for the current year.

Insider Activity at Sotera Health

In other Sotera Health news, Director Gtcr Investment Xi Llc sold 8,000,000 shares of the company's stock in a transaction dated Friday, September 5th. The stock was sold at an average price of $15.11, for a total transaction of $120,880,000.00. Following the sale, the director owned 41,215,301 shares in the company, valued at $622,763,198.11. This represents a 16.26% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Pincus & Co. Warburg sold 12,000,000 shares of the company's stock in a transaction dated Friday, September 5th. The stock was sold at an average price of $15.11, for a total value of $181,320,000.00. Following the sale, the director owned 61,822,952 shares in the company, valued at approximately $934,144,804.72. This trade represents a 16.26% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 20,126,611 shares of company stock worth $304,273,888. 55.12% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on SHC. Barclays upped their price target on Sotera Health from $17.00 to $19.00 and gave the company an "overweight" rating in a research note on Thursday, October 2nd. Weiss Ratings reaffirmed a "sell (d)" rating on shares of Sotera Health in a research note on Wednesday, October 8th. Finally, Wall Street Zen raised Sotera Health from a "buy" rating to a "strong-buy" rating in a research note on Saturday, August 16th. Four research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, Sotera Health has an average rating of "Moderate Buy" and a consensus price target of $17.20.

About Sotera Health

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.

Want to see what other hedge funds are holding SHC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sotera Health Company (NASDAQ:SHC - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.